Aeterna Zentaris - CSCI Short-Term Debt to Capital

CSCI (COSCIENS Biopharma Inc.) - company brandmark

This chart of the current market value of COSCIENS Biopharma Inc. (CSCI) reflects a debt-to-equity ratio of 0.05. The company is currently integrating an acquired private biotech firm, temporarily pausing mergers to focus on developing its own endocrine research. The Canadian enterprise relies on unique patents and global distribution channels, while demand for its therapies remains constant regardless of market cycles.

CSCI - COSCIENS Biopharma Inc Short-Term Debt to Equity Ratio over the range 08/10/2024 - 09/14/2025

Analytical breakdowns for COSCIENS Biopharma Inc.

- stock value and consensus price forecast:
Price Chart Aeterna Zentaris|CSCI - Forecast Levels Chart
- issuer market value details:
Market Capitalization COSCIENS Biopharma Inc|CSCI - Total Enterprise Value
- book capitalization information:
Book Value per Share COSCIENS Biopharma|CSCI - Company Net Assets|Market Capitalization to Book Value Ratio cosciensbio.com|CSCI - Company Total Asset Base
- debt level and financial liquidity data:
Total Debt to Capital COSCIENS Biopharma Inc.|CSCI - Long-Term Debt to Capital|Short-Term Debt to Equity COSCIENS Biopharma|CSCI - Company Debts|Debts to Book Capitalization COSCIENS Biopharma Inc|CSCI - Long-Term Debt Volume|Company Current Liabilities COSCIENS Biopharma
General company analysis:Aeterna Zentaris
Brand item of COSCIENS Biopharma

For the COSCIENS Biopharma Inc. (CSCI) biopharmaceutical ecosystem, which is developing the commercialization of orphan drugs, the company's short-term leverage history visualizes the balance between debt capital and equity. This ratio compares liabilities with a maturity of more than one year to total capital, allowing investors to assess financial stability and the risk of excessive debt load while scaling the proprietary Macrilen molecules.

Main competitors

Short-Term Debt to Equity Vertex Pharmaceuticals Inc. (VRTX)|ALNY: Current Liabilities to Equity|Short-Term Debt to Capital INSM (Insmed Incorporated)|unither.com (UTHR) - Current Liabilities to Capital|BioMarin - Short-Term Debt to Capital|BridgeBio Pharma (BBIO) - Short-Term Debt to Equity Ratio|BGM: Short-Term Debt to Capital|COGT - Short-Term Debt to Capital Coefficient|XERS (Xeris Biopharma) - Short-Term Debt to Capital|Short-Term Debt to Capital kerostx.com|Short-Term Debt to Equity Arcturus Therapeutics Holdings Inc. (ARCT)|Short-Term Debt to Equity ETON (Eton Pharmaceuticals Inc)|Short-Term Debt to Capital KMDA (Kamada Corp)|Short-Term Debt to Capital Coefficient Fulcrum Corp (FULC)|ABEO: Short-Term Debt to Equity Ratio|Current Liabilities to Equity MREO|PLX: Short-Term Debt to Capital|Current Liabilities to Capital Pliant Therapeutics, Inc. (PLRX)|APLT (Applied Therapeutics) - Short-Term Debt to Capital|Short-Term Debt to Capital Ratio RNTX (Aileron Therapeutics)|Short-Term Debt to Equity Ratio GELS (Gelteq Limited)|AYTU (aytubio.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Chemomab Therapeutics Ltd. CMMB|SRXH (SRx Health Solutions Inc) - Current Liabilities to Equity|Polyrizon Ltd. - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital AEZS (Aeterna Zentaris)|CYTH: Short-Term Debt to Capital|Inozyme Pharma (INZY) - Short-Term Debt to Capital|Short-Term Debt to Equity Reneo Pharmaceuticals, Inc.